Presley et al. previously reported that broad‐based genomic sequencing was not associated with better survival than routine EGFR and/or ALK testing among advanced NSCLC patients receiving treatment in the community oncology setting.39 This evidence concerns the gene EGFR and non-small cell lung carcinoma.